Gynecology, Menopause and Family Planning
Tuesday, March 22, 2016
| 08:30-10:00 | HPV: SETTING THE SCENE IN AUSTRALIA Supported in part by Abbott Supported in part by BD Supported in part by Seegene Supported in part by Seqirus |
| Capsule | Australia is leading the world in the efforts to control cervical cancer. The most advanced vaccination program has been complemented by an imminent transition to an HPV based screening program. Reductions in high grade abnormalities have already been documented and reductions in cervical cancer are expected in the coming years. |
| Chairperson | Suzanne Garland, Australia F. Xavier Bosch, Spain |
| 08:30-08:40 | Introduction 10 years into HPV vaccination: The world’s perspective in cervical cancer prevention in 2016 F. Xavier Bosch, Spain |
| 08:40-08:55 | The implementation of the National HPV Vaccination program in Australia and role of the National HPV Vaccination Program Register Julia Brotherton, Australia |
| 08:55-09:10 | Phase 4 surveillance through the National Surveillance Program: Reduction in viral circulation, and precancerous lesions Sepehr Tabrizi, Australia |
| CONTROVERSIAL TOPICS IN HPV PREVENTION: | |
| 09:10-09:20 | Vaccine safety and crisis management Nigel Crawford, Australia |
| 09:20-09:30 | HPV vaccination and HPV screening in men-who-have-sex with men Andrew Grulich, Australia |
| 09:30-09:40 | Indigenous populations: Screening participation and abnormality rates – the linkage study John Condon, Australia |
| HPV self-sampling: An alternative for under-screened women Dorota Gertig, Australia |
|
| 09:40-10:00 Discussants |
Discussion: Karen Canfell, Australia Suzanne Garland, Australia F. Xavier Bosch, Spain |
| Questions to the panelists and audience: 1. Minimal surveillance protocols for developing countries 2. Herd effects VS. vaccine coverage VS. gender neutral vaccinations 3. HIV cohorts: How to prevent HPV related cancers |
| 10:00-10:20 |
Coffee break |
| 10:20-11:50 | THE FUTURE OF VACCINATION AND SCREENING |
| 10:20-10:35 | The Renewal of the National Cervical Screening program and the 2017 transition to primary HPV screening Marion Saville |
| 10:35-10:50 | The future of cervical screening in the era of HPV vaccination: Role of the Compass trial Karen Canfell, Australia |
| 10:50-11:05 | The future of cervical cancer control: HPV vaccination and screening The HPV FASTER trials and consortium F. Xavier Bosch, Spain |
| 11:05-11:20 | Next-generation vaccines and the Australian HPV FASTER study Suzanne Garland, Australia |
| 11:20-11:45 Discussants |
Discussion: Karen Canfell, Australia Suzanne Garland, Australia F. Xavier Bosch, Spain |
| Questions to the panelists and audience: 1. Prophylactic vaccines as part of the treatment for GW, RRP and CIN 2. One dose vaccination regime 3. HPV tests for screening: Clinically validated assays |
|
| 11:45-11:50 | Closure Suzanne Garland, Australia |
| 11:50-12:10 |
Break |
| 12:10-13:40 |
TREATMENT OF ADENOMYOSIS AND FIBROIDS |
| Capsule | Fibroids are encountered in increasing frequency in IVF patients as the mean age of infertility patients rises. Do we have to treat them all? |
| Chairperson | Luk Rombauts, Australia Paula Briggs, UK |
| 12:10-12:40 | Surgical technique for adenomyosis Jacques Donnez, Belgium |
| 12:40-13:10 | What evidence supports that fibroids should be operated before IVF? Zion Ben Rafael, Israel |
| 13:10-13:40 | Medical management of fibroids Jacques Donnez, Belgium |
| 13:40-14:30 |
Lunch Break |
| 14:30-16:00 | EVIDENCE-BASED BEST CLINICAL PRACTICE FOR MANAGING MENOPAUSAL SYMPTOMS Supported in part by Fotona |
| Capsule | There is substantial uncertainty amongst practitioners as to when and what hormonal/non-hormonal therapy to prescribe. This session will provide clinicians with an evidence-based blueprint |
| Chairperson | Susan Davis, Australia Sven O. Skouby, Denmark |
| 14:30-14:50 | Estrogen and progestin therapy: What to prescribe and why Sonia Davison, Australia |
| 14:50-15:10 | Old and new options: Tibolone and TSEC Sven O. Skouby, Denmark |
| 15:10-15:35 | Non-hormonal therapies for vasomotor symptoms: What works? Martha Hickey, Australia |
| 15:35-16:00 | Erbium laser treatment of vaginal atrophy: Comparison with hormonal replacement therapy (HRT): 18 months follow-up Adrian Gaspar, Argentina |
| 16:00-16:30 |
Coffee break |
| 16:30-18:00 | MENOPAUSE: THE NEEDS AND THE CHALLENGES |
| Capsule | Many studies claim that we overreacted to the WHI results. Are women suffering and why has MHT use never bounced back? |
| Chairpersons | Susan Davis, Australia Sonia Davison, Australia |
| 16:30-16:55 | Menopause: How long does it last and how bad are the symptoms? Roisin Worlsey, Australia |
| 16:55-17:15 | The WHI: Have we reached the wrong conclusions? Robert Langer, USA |
| 17:15-17:35 | Premature Ovarian Insufficiency – meeting the treatment goals Rodney Baber, Australia |
| 17:35-18:00 | “Doctor I can’t sleep!” Darren Mansfield, Australia |
Wednesday, March 23, 2016
| 08:30-09:15 | ENDOMETRIOSIS |
| Chairpersons | Jacques Donnez, Belgium Luk Rombauts, Australia |
| Debate: In Endometriosis and infertility Immediate ART: Luk Rombauts, Australia Immediate surgery: Kate McIlwaine, Australia Discussion |
|
| 09:15-10:00 | FAMILY PLANNING Supported by MSD |
| Chairpersons | Jacques Donnez, France Luk Rombauts, Australia |
| Conflicts in contraception Ann Hotchin, Australia Rochelle Hamilton, Australia |
| 10:00-10:20 |
Coffee break |
| 10:20-11:50 | MENOPAUSE, BEYOND FLUSHES/FLASHES AND SWEATS Supported in part by Fotona |
| Capsule | The hormonal changes during menopause result in an array of health consequences, some of which will be addressed in this session |
| Chairpersons | Robert Langer, USA Martha Hickey, Australia |
| 10:20-10:50 | Women, Libido and Desire. An approach to rekindling desire Cyndi Darnell, Australia |
| 10:50-11:20 | Vulvar and vaginal atrophy: Causes, presentation and treatment Beverley Vollenhoven, Australia |
| 11:20-11:50 | Erbium Laser for Pelvic Floor Dysfunction: Australian experience Else de Wit, Australia |
| 11:15-12:10 |
Break |
| 12:10-13:40 | BREAST CANCER |
| Chairpersons | Bruce Mann, Australia Roisin Worlsey, Australia |
| 12:10-12:40 | Controversies in mammographic screening explored Bruce Mann, Australia |
| 12:40-13:10 | Managing menopausal symptoms after breast cancer Martha Hickey, Australia |
| 13:10-13:40 | Genetic testing for cancer predisposition: Who should be tested and how? Paul James, Australia |
| 13:40-14:30 |
Lunch Break |
| 14:30-16:00 | FAMILY PLANNING |
| Capsule | Thromboembolism is a threatening complication of OC’s. What is the difference between various preparations in the market? |
| Chairpersons | Sven O. Skouby, Denmark Kathleen McNamee, Australia |
| 14:30-14:50 | Mechanism of OC’s related thrombosis Sven O. Skouby, Denmark |
| 14:50-15:15 | Difference in thromboembolic risk by pill type: Managing the risk Kathleen McNamee, Australia |
| 15:15-15:40 | Recent advances in emergency contraception Paula Briggs, UK |
| 15:40-16:00 | Use of IUS in Nulipara: Good or bad medicine Gab Kovacs, Australia |
| 16:00-16:30 |
Coffee Break |
| 16:30-18:00 | PROTECTING THE SKELETON |
| Capsule | The prevention and treatment of osteoporosis is an important component of the care of women, but who to screen and when to intervene can be challenging. |
| Chairperson | Sven O. Skouby, Denmark Paula Briggs, UK |
| 16:30-17:00 | Deciding who and when to screen for osteoporosis Susan Davis, Australia |
| 17:00-17:30 | The WHI and osteoporosis Robert Langer, USA |
| 17:30-18:00 | Preventing bone loss and fracture: How and when to treat Peter Ebeling, Australia |